US biotech giant Amgen (Nasdaq: AMGN) today announced it has entered into a definitive agreement to acquire ChemoCentryx (Nasdaq: CCXI) for $52 per share in cash, representing an enterprise value of around $3.7 billion.
The transaction, which is one of the biggest M&A deals announced so far this year, is expected to close in the fourth quarter of 2022.
The offer price is a premium of nearly 116% to ChemoCentryx stock's closing price on Wednesday. Shares of ChemoCentryx, which were down nearly 34% this year as of last close, more than doubled in value to trade at $51.40 before the bell.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze